Robbie Stephens Cuts Chiron Rating
Analyst Michael King is disappointed with the FDA's delay in approval for the biotech firm's blood testing system
Robertson Stephens downgraded Chiron (CHIR ) to market underperform.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
You might like:
- Fewest Jobless Claims Since 1973 Show Firm U.S. Job Market
- Greenwich Mansion Listings Pulled to Wait for a Better Day
- U.S. Stocks Climb With Treasuries as Dollar Slides: Markets Wrap
- The U.K.'s $86 Billion Pension Problem Is About to Solve Itself
- Germans Are Going Wild for a Show Set During the Dawn of the Nazis